Monoclonal Antibodies Market Size, Share, Growth Analysis, By Source type(Murine, Chimeric, Humanized, Human), By Production Type(In Vivo, In Vitro), By Application(Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases), By End-use(Hospitals, Specialty Centers, Others), By Region - Industry Forecast 2024-2031

North America remained the largest market in 2023, accounting for a share of around 46.1%, mainly due to an advanced healthcare system and high patient awareness, and promising future for research in cancer. This area benefits from massive funding by governments to advance cancer research, thereby rapidly transforming the creation and availability of monoclonal antibodies for medicinal use. The presence of these important industry participants such as Pfizer Inc., Amgen, Inc., and Merck & Co. helps generate a competitive environment conducive to cooperation and innovation. The North American market is expected to continue its leadership position while being poised to have stable growth in the next few years through these companies continuing their efforts on their R&D operations. 

Besides several critical factors, Asia-Pacific is expected to grow at the fastest rate in the forecast period—12.1%. The rising disposable income of the region, combined with a highly significant patient pool requiring mAb cancer treatments, further expands market potential. Sustained investment in high-tech medical technology and increasing attention to health care improvement also form a propitious environment for the development of mAb. Pharmaceutical industries in countries such as China and India have thus enormous potential, hence are particularly inviting for investments in clinical research. This focus on R&D is predicted to drive the growth of the monoclonal antibodies market in the region significantly.